

Ricola Group AG

Disclosure Report
Date Submitted: December 1st, 2023

© B Lab 2023



Disclosure Materials

Certified B Corporations must complete a Disclosure Questionnaire to identify potentially sensitive issues related to the company (e.g. historical fines, sanctions, material litigation, or sensitive industry practices).

This component does not affect the company's score on the B Impact Assessment. If the company answers affirmatively to any items in the Disclosure Questionnaire that B Lab deems relevant for public stakeholders, then, as a condition of their certification, the company must:

- Be transparent about details of the disclosure issues identified on the company's public B Impact Report
- 2) Describe how the company has addressed this issue
- 3) Demonstrate that management practices are in place to avoid similar issues from arising in the future, when necessary.

In all cases, the Standards Advisory council reserves the right to refuse certification if the company is ultimately deemed not to uphold the spirit and integrity of the community.

In addition to the voluntary indication of sensitive issues in the Disclosure Questionnaire, companies pursuing Certification also are subject to a background check by B Lab staff. Background checks include a review of public records, news sources, and search engines for company names, brands, executives/founders, and other relevant topics.

Sensitive issues identified through background checks may or may not be within the scope of questions in the Disclosure Questionnaire, but undergo the same review process and are subject to the same possible review by the Standards Advisory Council, including ineligibility for B Corp Certification, required remediation, or disclosure.

This document contains a copy of the company's completed Disclosure Questionnaire and related disclosure documentation provided by the company



Disclosure Questionnaire

Industries and Products

Yes No Please indicate if the company is involved in production of or trade in any of the following. Select Yes for all options that **Animal Products or Services** $\boxed{}$ **Biodiversity Impacts** Chemicals \square **Disclosure Alcohol Disclosure Firearms Weapons** $\boxed{}$ **Disclosure Mining** $\boxed{}$ **Disclosure Pornography** $\boxed{}$ **Disclosure Tobacco** $\boxed{}$ **Energy and Emissions Intensive** $\overline{\mathbf{A}}$ <u>Industries</u> Fossil fuels \square Gambling **Genetically Modified Organisms** $\overline{\mathbf{A}}$ Illegal Products or Subject to $\overline{\mathbf{A}}$ **Phase Out** Industries at Risk of Human \square **Rights Violations Monoculture Agriculture** \square **Nuclear Power or Hazardous** \square **Materials** Payday, Short Term, or High **Interest Lending** Water Intensive Industries \square **Tax Advisory Services**

Outcomes & Penalties

	Yes	No
Please indicate if the company has had any formal complaint to a regulatory agency or been assessed any fine or sanction in the past five years for any of the following practices or policies. Check all that apply.		
Anti-Competitive Behavior		\checkmark
Breaches of Confidential Information		V
Bribery, Fraud, or Corruption		
Company has filed for bankruptcy		V
Consumer Protection	V	V
Financial Reporting, Taxes, Investments, or Loans		N
Hazardous Discharges Into Air/Land/Water (Past 5 Yrs)		N
Labor Issues		V
Large Scale Land Conversion, Acquisition, or Relocation		K
Litigation or Arbitration		
On-Site Fatality		V
Penalties Assessed For Environmental Issues		V
Political Contributions or International Affairs		K
Recalls		
Significant Layoffs		V
Violation of Indigenous Peoples Rights		N
Other		\triangleright



Practices

	Yes	No
Please indicate if the following statements are true regarding whether or not the company engages in the following practices. Check all that apply. If the statement is true, select "Yes." If false, select "No."		
Animal Testing		K
Company/Suppliers Employ Under Age 15 (Or Other ILO Minimum Age)		V
Company prohibits freedom of association/collective bargaining		\searrow
Company workers are prisoners		\searrow
Conduct Business in Conflict Zones		V
Confirmation of Right to Work		V
Does not transparently report corporate financials to government		N
Employs Individuals on Zero-Hour Contracts		N
Facilities located in sensitive ecosystems		N
ID Cards Withheld or Penalties for Resignation		\
No formal Registration Under Domestic Regulations		V
No signed employment contracts for all workers		V
Overtime For Hourly Workers Is Compulsory		V
Payslips not provided to show wage calculation and deductions		V

	Yes	No
Sale of Data		V
Tax Reduction Through Corporate Shells		V
Workers cannot leave site during non-working hours		V
Workers not Provided Clean Drinking Water or Toilets		\supset
Workers paid below minimum wage		N
Workers Under Bond		\checkmark
Other	\checkmark	

Supply Chain Disclosures

	Yes	No
Please indicate if any of the following statements are true regarding your company's significant suppliers.		
Business in Conflict Zones		\checkmark
Child or Forced Labor		\checkmark
Negative Environmental Impact		\vee
Negative Social Impact		\checkmark
Other		\checkmark



Disclosure Questionnaire Category: Consumer Protection

Issue Date	2019-2023
Topic	Company has received false advertising complaints about what is promoted on their labels.
Summary of Issue	One complaint alleged that consumers are misled by the language "naturally soothing" to believe that the product contains 100% natural ingredients. Four complaints allege that the label misrepresents the ingredients are active ingredients are herbal. One complaint alleges that the "max" strength lozenge misleads the consumer to believe it provides nasal decongestant action when it only provides temporary relief of minor irritation and pain associated with sore mouth and sore throat.
Size/Scope of Issue (e.g. \$ financial implication, # of individuals affected)	Between 2019 and 2023, the company has had 6 complaints.
Impact on Stakeholders	Ricola does not believe there is an impact on consumers because the label is not misleading, and, in all events, the label contains either the FDA-approved Drug Facts panel or Supplement Facts panel which provides information regarding ingredients, uses, dosage and other information.
Resolution	The two "naturally soothing" lawsuits were settled and dismissed. The four complaints relating to active ingredients being herbal are still pending, but the court has ruled that one of them is not suitable for class treatment. The company has not yet responded to the "max" strength lawsuit but will be doing so. The company has not paid any fines or been required to recall its products.
Implemented Management Practices	With regard to the four complaints alleging that the label misrepresents that the active ingredients are herbal, the company and an expert have confirmed that the active ingredient is herbal menthol. Accordingly, no new management practices have been implemented by the company.



Disclosure Questionnaire Category: Environmentally Intensive Industries - Water Intensive Industries

Topic	Water Intensive Industries
Summary of Issue	As a pharmaceuticals manufacturer, Ricola Group AG is in a Water Intensive Industry.
Size/Scope of Issue (e.g. \$ financial implication, # of individuals affected)	100% of the revenue comes from manufacturing and selling pharmaceuticals.
Impact on Stakeholders	Water intensive manufacturing activities, such as pharmaceuticals manufacturing, pose an environmental risk if not properly managed. However, the company operates in a region that is not water stressed.
Implemented Management Practices	The company manufactures products (herbal drop) with a water intensity of 507 liters/100kg. which is equivalent to 5070 liters/ton of product. The company analyzes the water intensity regularly and has a
	reduction target in production facility by 15% by 2025 vs 2019 per 100 kg bulk.
	In their everyday operations, the company manages water usage as part of their main production control system. This allows them to use the necessary amount of water for optimal cleaning of production plants. They've installed valves that open and close as needed, ensuring precise water usage at specific times.
	Water is 1 out of 6 key sustainability management topics at Ricola.



Disclosure Questionnaire Category: Other - Pharmaceutical Industry

Topic	Company produces and sells cough drops
Summary of Issue	Ricola is a cough drop producing company. They sell their products in retail and pharmacies, depending on the market. Ricola has R&D that focus on the development of new flavors of cough drops. The pharmaceutical ingredient in cough drops is the herb mixtures, containing 7 – 13 herbs from the Swiss mountains. The company controls the production process from extraction of the herbal substances up to the production of the drops. They have very limited direct sales in 2 Ricola-stores worldwide. 99.9% of their sales go through independent distributors or are sold to retail and pharmacies.
	100% of their drops are Ricola-branded and they only have over-the-counter products. Depending on the market, products are sold as pharma or as food.
Size/Scope of Issue (e.g. \$ financial implication, # of individuals affected)	100% of their revenue comes from their Ricola-branded drops. All their products are over-the-counter products. Depending on the market, products are sold as pharma or as food.
Impact on Stakeholders	Although the pharmaceutical industry on its face would seem like an industry with a positive impact by developing products that save lives, several aspects of the industry's current business model are potentially controversial because of the potential of making profit-driven decisions that benefit the company while harming public health. Research & development (R&D) investment decisions determine which healthcare solutions are developed and often overlook health solutions for those most in need. The quality and safety of products are at risk of compromise depending on manufacturing and distribution practices, which can result in ineffective treatments or adverse effects on consumers. Pricing decisions directly affect the affordability and accessibility of products globally. At each stage of the pharmaceutical value chain, companies have a large potential impact on the state of global health. Given the limited scope of Ricola Group's products, the company is not required to meet all B Lab's Pharmaceutical



	Risk Standards as most of the requirements are not applicable to the company's activities.
Implemented Management Practices	All stages of the drug life cycle are relevant to Ricola's operations. Pharmaceutical activities according to the permission granted by a competent authority. Ricola AG manufactures non-sterile solid dosage forms: hard candies, pastilles/pearls (soft candies) and tea granules. Ricola AG has various pharmaceutically relevant activities. The operating license of Swissmedic is for the manufacture of active pharmaceutical ingredients, the manufacture of intermediates and medicinal products, quality control of medicinal products and wholesale trade in medicinal products, restricted to dispensing categories D and E. In Switzerland, cough and throat lozenges are registered with Swissmedic as medicinal products of list D and E registered. In Canada, all products are registered as Natural Health Products with Health Canada. Ricola AG is registered as a manufacturer under number 12455. In the USA, most products are listed as OTC products with the FDA. Ricola AG is registered with the FDA under the VIN number 1000170866. Ricola is GMP and GDP (Good Distribution Practice) certified. Every stage of the drug life cycle is regularly controlled within internal and external inspections (the latter, among others, by authorities). The company also shared that it does not engage in any political activities, including lobbying and advocacy practices.
Report	Ricola's Code of Conduct



Disclosure Questionnaire Category: Environmentally Intensive Industries - Energy and Emissions Intensive Industries

Topic	Energy and Emissions Intensive Industries
Summary of Issue	As a pharmaceuticals manufacturer, Ricola Group AG is in an Energy Intensive Industry.
Size/Scope of Issue (e.g. \$ financial implication, # of individuals affected)	100% of the revenue comes from manufacturing and selling pharmaceuticals.
Impact on Stakeholders	Energy intensive manufacturing activities, such as pharmaceuticals manufacturing, pose an environmental risk due to the emissions produced by such energy use. The extent of environmental impact is dependent on the energy sources utilized and management practices in place to manage energy use.
Implemented Management Practices	The company manufactures products (herbal drop) with an energy intensity of 0.113 CO2/kg of product for Scope 1 and Scope 2 emissions.
	Within Scope 1 and Scope 2 the energy sources are hydro power, solar, biogas and natural gas. The emissions from Scope 1 and Scope 2 are low compared to the industry benchmark (Food processing - sugar) of 0.83 CO2/kg. This forms 3% of their emissions and the rest are Scope 3 (raw materials).
	In scope 1+2, they have been measuring their emissions for over a decade. There are mandatory climate reduction goals with the Swiss Government, which Ricola has always complied with. This included changing their heating system (heat recovery) and the continuous switch to renewable energy sources (hydropower solar and biogas) in the past years.
	For Scope 3, they have defined SBTi goals and have been working on reduction of their emissions for years. In the last year, they changed their sourcing to a more sustainable sugar with lower emissions. Furthermore, they are working on making



their packaging more sustainable and less energy-intensive (e.g. bluemint steel for cans instead of conventional steel), and optimizing their logistics for up - and downstream transport.

Ricola is part of a food-industry association and are reporting their energy usage and carbon emissions of scope 1 & 2 regularly to the association. They are also a part of an industry-wide sustainability board, where mitigations and industry-wide goals are discussed.